Eli Lilly Poised for Massive Growth on Obesity Drug and Robust Pipeline
• Eli Lilly's new obesity drug could generate over $62B in sales by 2030 • Analyst boosts Eli Lilly price target to $1,000 based on competitive advantages • Demand is far outstripping supply for obesity drugs currently • Commercial dynamics favor Eli Lilly and Novo Nordisk in obesity market • Beyond obesity, Eli Lilly has treatments in development in neuroscience, oncology, and immunology that could boost growth